Top news of the week: 17.11.2020.
#innovation #biotechnology #biospace #lifesciences #pharmaceuticals #NBTintheNews
Companies And Industries
Mispro’s Emerging Business Model Helps Biopharma Companies Get to Market Faster
#biospace #lifesciences #biotechnology #pharmaceuticals #innovation
https://t.co/EoSczMo5xM
OpenMispro’s Emerging Business Model Helps Biopharma Companies Get to Market Faster
This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing.
As Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma https://t.co/oNP1PFrhNJ
OpenAs Urovant gears up for vibegron FDA decision, the biotech gets snapped up by Sumitovant Biopharma
Urovant began life as an offshoot of Vivek Ramaswamy’s Roivant goliath, but is now firmly a part of the Sumitovant Biopharma family after the life science company bought up the rest of its ...
German biotech Catalym has closed a €50 million series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). https://t.co/Nc85XJNQzh
OpenGerman biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy
Catalym has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15).
After a little more than two years in charge, Gujrathi is leaving Gossamer Bio, although she will continue in an advisory role. https://t.co/zeBsQzvKqA
OpenGossamer rehires Hasnain as CEO after midphase flop
Gossamer Bio has reappointed Faheem Hasnain as CEO one month after its lead drug failed in phase 2. Hasnain, the former CEO of Receptos, ran Gossamer Bio early in its history before handing ...
Vaccines could “effectively end” the pandemic next year, @ScottGottliebMD says.
https://t.co/rCDP2eZI5L
Open‘We could effectively end this pandemic in 2021’ with Pfizer and Moderna Covid vaccines
"If these full data sets hold, when the full data comes out, we may have two highly effective vaccines against Covid," Dr. Scott Gottlieb told CNBC on Monday.
RT @viruswhiz: Things are looking promising for mRNA vaccines! It's still early in the trials for Pfizer/BioNTech and Moderna's candidates, but 🤞 these preliminary results hold up.
https://t.co/dGt7AoLAqe
OpenModerna says its COVID-19 vaccine is nearly 95 percent effective
Another coronavirus vaccine appears to be very effective in preventing people from developing COVID-19 symptoms.
Patent thickets and regulatory challenges cited as major factors limiting price reductions in the biologic drug space #NBTintheNews https://t.co/XGhjkn0WwC
OpenPatent Thickets and Regulatory Challenges Cited as Major Factors Limiting Price Reductions in the Biologic Drug Space
The world-wide market share of biologic drugs is advancing at a staggering pace, with some estimates ranging from $ 300 billion to $452 billion in...
RT @SynBioOxford: Did you know that SynBio has applications in the fashion industry? To find out more, join us on November 23 for a webinar with @idtdna and @colorifix! Please sign up on Eventbrite
https://t.co/kTH7bGOccr
OpenActions and Detail Panel
Join us to get an introduction to Synthetic Biology at IDT and Colorifix!